142407-06-5

Upstream product

• 142407-05-4 2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]quinoline 
• 114433-94-2 1-(4-Fluorophenyl)-3-isopropylpropan-1,3-dione 
• 15793-77-8 2-hydrazinoquinoline 

Downstream Products

• 142407-07-6 trans-7-[(4-fluorophenyl)-3-(1-methylethyl)-1-(2-quinolinyl)-1H-pyrazol-4-yl]-5-hydroxy-3-oxo-6-heptenoic acid, ethyl ester 
• 141046-31-3 trans-3-[5-(4-fluorophenyl)-3-(l-methylethyl)-1-(2-quinolinyl)-1H-pyrazol-4-yl]-2-propenal 
• 141046-40-4 (E)-3-<1-(3,4-dihydro-2-quinolinyl)-5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-4-yl>-2-propenal 
• 141046-29-9 (E)-3-[5-(4-Fluoro-phenyl)-3-isopropyl-1-quinolin-2-yl-1H-pyrazol-4-yl]-acrylic acid ethyl ester 

Relevant academic research and scientific papers

Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5- disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones

A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the str

Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Certain trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)ethyl]- or ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones and the corresponding ring-opened acids, esters and N-oxides derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-m